RNS Number : 1706K
Genedrive PLC
30 December 2020

genedrive plc
("genedrive" or the "Company")

Result of AGM

Genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that at the Annual General Meeting, held today, all resolutions proposed were duly passed.

For information, details of the proxy voting are shown below:

	Votes For	Vote For (as % of votes cast)	Votes Against	Votes Against (as % of votes cast)	Votes withheld
1 Receive the Annual report and accounts for the Company	18,105,091	99.6%	76,514	0.4%	98,780
2 Approve the Directors Remuneration Report	18,004,341	99.2%	143,950	0.8%	131,981
3 Re-appoint Tom Lindsay as a director	18,046,634	99.4%	105,545	0.6%	128,206
4 Re-appoint Chris Yates as a director	18,049,104	99.4%	103,075	0.6%	128,206
5 Re-appoint David Budd as a director	18,020,957	99.2%	148,510	0.8%	110,918
6 Re-appoint Matthew Fowler as a director	18,049,104	99.4%	103,075	0.6%	128,206
7 Re-appoint Ian Gilham as a director	16,874,853	99.3%	120,159	0.7%	1,285,373
8 Re-appointment of RSM UK as auditors of the Company	18,062,908	99.6%	79,628	0.4%	137,849
9 Directors authority	17,902,887	98.7%	229,670	1.3%	147,828

to allot shares					
10 Disapplication of pre-emption rights	16,773,042	92.6%	1,341,787	7.4%	165,041

The full text of each of the resolutions is set out in the notice of Annual General Meeting, copies of which are available on the Company's website (www.genedriveplc.com).

For further details please contact:

genedrive plc +44 (0)161 989 0245
David Budd: CEO / Matthew Fowler: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker) +44 (0)20 7418 8900
James Steel / Oliver Jackson

finnCap (Joint Broker) +44 (0)20 7220 0500
Geoff Nash / Kate Bannatyne / Alice Lane

Walbrook PR Ltd (Media & Investor Relations) +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Paul McManus / Anna Dunphy +44 (0)7980 541 893 / +44 (0)7876 741 001

About genedrive plc (http://www.genedriveplc.com)
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently released a high throughput SARS-CoV-2 assay and has in development a Genedrive® Point of Care version of the assay, both based on Genedrive® chemistry.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGBDBDDLSXDGGG